P53 Immunolabeling in EUS-FNA Biopsy can Predict Low Resection Rate and Early Recurrence in Resectable or Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Therapy.
Minoru OshimaKeiichi OkanoHideki KamadaHironobu SutoYasuhisa AndoEmi IbukiRyo IshikawaTsutomu MasakiReiji HabaYasuyuki SuzukiPublished in: Journal of hepato-biliary-pancreatic sciences (2022)
Pretreatment abnormal labeling of p53 in EUS-FNA specimen was associated with a lower resection rate and an early recurrence in R or BR PDAC cases.